DECLARATION is a Phase 3, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of VYD2311 in the prevention of ...

The US Food and Drug Administration (FDA) has given an emergency use authorization to the first commercial laboratory test to detect neutralizing antibodies against SARS-CoV-2, the virus that causes ...

Although the 'emergency' phase of the COVID-19 pandemic may be over, it is still ongoing, and thousands of people still die from the disease every week. The virus also continues to mutate, and new ...

In a recent study published in Frontiers, researchers investigated the transmission- and immunoglobulin G (IgG) viral neutralization potential of coronavirus disease 2019 (COVID-19) booster vaccine ...

A recent study by Ohio State researchers shows that a new omicron subvariant of COVID-19 can be neutralized by the dual-strain vaccine, preventing the worldwide escalation of cases that was initially ...

An antibody developed by researchers works against a wide range of COVID-19 variants and related coronaviruses, including past, present and potentially future strains. A monoclonal antibody appears ...

Four years ago, on November 30, 2019, the first confirmed case of COVID-19 was detected in a man in Wuhan, China. It would still be over a month before the SARS-CoV-2 virus was fully identified, but ...

Invivyd authors evaluated early side effects of prior low-dose investigational monoclonal antibody adintrevimab from the EVADE study, demonstrating minimal tolerability issues; Re ...

Shionogi & Co. looks set to put its COVID-19 vaccine into practical use by the end of March 2022 following a government ...